McKenna Mark C. 4
4 · Spyre Therapeutics, Inc. · Filed Feb 5, 2024
Insider Transaction Report
Form 4
McKenna Mark C.
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-02-01+40,000→ 40,000 totalExercise: $25.86Exp: 2034-02-01→ Common Stock (40,000 underlying)
Footnotes (1)
- [F1]This option represents a right to purchase 40,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on February 1, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.